NCT07480941 2026-03-18
DUAL-CAR-NK-GB
Beijing Biotech
Phase 1 Recruiting
Clinical Trials
43 trialsNCT06344130 2026-03-17
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT04485559 2026-03-16
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
University of California, San Francisco
Phase 1 Recruiting
NCT03896568 2026-03-05
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06917885 2026-03-05
CUE-102 in Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05538130 2026-03-04
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
Phase 1 Recruiting
NCT03911388 2026-02-17
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05565118 2026-02-17
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
Case Comprehensive Cancer Center
Phase 1 Recruiting
NCT06650163 2026-02-05
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT05660369 2026-02-04
CARv3-TEAM-E T Cells in Glioblastoma
Massachusetts General Hospital
Phase 1 Recruiting
NCT05355701 2026-02-03
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT05762419 2026-01-28
FUS Etoposide for DMG
Columbia University
Phase 1 Recruiting
NCT06482905 2026-01-06
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Tcelltech Inc.
Phase 1 Recruiting
NCT06724926 2026-01-02
Concurrent Azeliragon With Craniospinal Irradiation
NYU Langone Health
Phase 1 Recruiting
NCT07306299 2025-12-29
A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Recruiting
NCT04541082 2025-12-18
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT05686798 2025-12-16
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Henry Ford Health System
Phase 1 Recruiting
NCT04185038 2025-12-15
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Seattle Children's Hospital
Phase 1 Recruiting
NCT05030298 2025-11-21
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
Mayo Clinic
Phase 1 Recruiting
NCT05293197 2025-11-20
SONOKID
Assistance Publique - Hôpitaux de Paris
Phase 1 Recruiting
NCT06326411 2025-11-10
NST-628
Nested Therapeutics, Inc
Phase 1 Recruiting
NCT07223034 2025-11-04
A Study of 177Lu-PSMA-617 in People With Gliomas
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06964737 2025-10-29
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT06169280 2025-10-06
Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma
Northwestern University
Phase 1 Recruiting
NCT04772456 2025-09-22
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
University of Maryland, Baltimore
Phase 1 Recruiting
NCT07179328 2025-09-17
Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy
Sunnybrook Health Sciences Centre
Phase 1 Recruiting
NCT04099797 2025-09-04
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Baylor College of Medicine
Phase 1 Recruiting
NCT06126744 2025-09-02
PuMP
Duke University
Phase 1 Recruiting
NCT07025018 2025-08-01
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
Hutchmed
Phase 1 Recruiting
NCT06624371 2025-07-22
AflacBT2303
Emory University
Phase 1 Recruiting
NCT05609994 2025-07-18
ViCToRy
Duke University
Phase 1 Recruiting
NCT06942104 2025-07-18
Imaging of Solid Tumors Using 18F-TRX
University of California, San Francisco
Phase 1 Recruiting
NCT06428045 2025-06-22
STARLITE
University of Miami
Phase 1 Recruiting
NCT05226494 2025-06-04
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
NanoPharmaceuticals LLC
Phase 1 Recruiting
NCT05698524 2025-05-20
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
Phase 1 Recruiting
NCT04254419 2025-05-13
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
Nationwide Children's Hospital
Phase 1 Recruiting
NCT04323046 2025-05-04
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
University of California, San Francisco
Phase 1 Recruiting
NCT05460507 2025-03-30
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Plus Therapeutics
Phase 1 Recruiting
NCT05298995 2025-02-05
GD2-CAR T Cells for Pediatric Brain Tumours
Bambino Gesù Hospital and Research Institute
Phase 1 Recruiting
NCT04540107 2025-01-10
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
University of California, San Francisco
Phase 1 Recruiting
NCT03739411 2024-11-19
Hyperpolarized Imaging in Diagnosing Participants With Glioma
University of California, San Francisco
Phase 1 Recruiting
NCT06585527 2024-10-31
Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma
Beijing Neurosurgical Institute
Phase 1 Recruiting
NCT06305910 2024-03-12
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
OX2 Therapeutics
Phase 1 Recruiting